Glaukos (GKOS) Stock

GKOS has submitted a New Drug Application for its Epioxa to the FDA.

Glaukos Corporation (GKOS) is set to increase its sales at an annual growth rate of around 20% until fiscal year 2027, possibly reaching $680 million in revenue and $90-$100 million in post-tax earnings. The stock is currently priced at 21 times its sales, reflecting strong growth expectations, but there is a 27% margin of safety at the current price. The company's effective asset management and solid cash flow contribute to its sustainable growth, mainly fueled by the adoption of iDose TR and iStent infinite in both domestic and international markets.

This Analyst Blog features companies like Intuitive Surgical, Globus Medical, Glaukos, Veracyte, and Inogen.

GKOS is still seeing strong demand for its products and is growing in new markets. There is a promising development pipeline that brings hope for the future.

In this article, we talk about five medical device stocks: ISRG, GMED, GKOS, VCYT, and INGN. These stocks saw growth in 2024, even with ongoing difficulties, and they present a promising investment chance for 2025.

The main figures for Glaukos (GKOS) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be useful to compare some important metrics with Wall Street predictions and the results from the same period last year.

The call began at 4:30 PM ET on November 4, 2024, for Glaukos Corporation's Q3 2024 earnings. Key company participants included Chris Lewis, Tom Burns, Joe Gilliam, and Alex Thurman. Various analysts from firms like Stifel, Wells Fargo, and JPMorgan also joined the call.

Glaukos (GKOS) reported a quarterly loss of $0.28 per share, which is better than the Zacks Consensus Estimate of a $0.52 loss. This is an improvement compared to a loss of $0.50 per share from the same period last year.

Glaukos (GKOS) has the right mix of two important factors that could lead to a strong earnings report soon. Be ready for the main expectations.